ClinicalTrials.gg
CompletedNCT03827018Updated Oct 23, 2023Results posted

KPL-301 for Subjects With Giant Cell Arteritis

A Phase 2 interventional study of mavrilimumab and placebo in Giant Cell Arteritis, sponsored by Kiniksa Pharmaceuticals, Ltd.. Completed at 49 sites in 15 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Kiniksa Pharmaceuticals, Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2018, registered Jan 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Giant Cell Arteritis with a site in United States — 8 open to participants now, 8 under way, 1 of them phase 3. Giant Cell Arteritis · United States.

Enrollment
10th of 20
70 · median 68
Started
2018
with 3 others
Phase 2
7 of 35
2 open now
Registered
26th of 35
by date

Among the 35 studies in Giant Cell Arteritis with a site in United States, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2018, is one of 7 in phase 2, and was the 26th registered.

Giant Cell Arteritis

149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.

Browse Giant Cell Arteritis studies →

Open to participants now

8 of the 35 studies in Giant Cell Arteritis with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Giant Cell Arteritis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).

Read the detailed description

This Phase 2 randomized, double-blind, placebo-controlled proof of concept study will evaluate the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in subjects with GCA. The study will consist of a screening period (up to 6 weeks), a 26-week double-blind placebo-controlled period during which subjects will receive blinded mavrilimumab or placebo co-administered with a 26-week corticosteroid taper, and a 12-week washout safety follow-up period during which subjects will discontinue and wash off blinded mavrilimumab or placebo.

03

Conditions studied

  • Giant Cell Arteritis

Browse trials for

Keywords

  • GCA
  • temporal arteritis
  • Horton's disease
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Selected Inclusion Criteria:

  1. Subjects with new-onset or relapsing/ GCA.
  2. Westergren erythrocyte sedimentation rate > 30 mm/hour or c-reactive protein ≥ 1 mg/ dL.
  3. Remission of GCA at or before Day 0.
  4. Female subjects must be or permanently sterile following documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation or having a male partner with vasectomy as affirmed by the subject, or nonpregnant, nonlactating, and if sexually active having agreed to use a highly effective method of .
  5. Male subjects must have documented vasectomy or if sexually active must agree to use a highly effective method of contraception with their partners of .

Selected Exclusion Criteria:

  1. Transplanted organs (except corneal transplant performed more than 3 months prior to randomization).
  2. Concurrent enrollment in another interventional clinical study.
  3. Treatment with non-biologic drug therapy within 4 weeks or 5 half-lives of the study agent, whichever was longer, prior to screening.
  4. Cell-depleting biological therapies within 12 months prior to Day 0, or noncell-depleting biological therapies within 8 weeks (or 5 half-lives, whichever is longer) prior to screening.
  5. Treatment with alkylating agents within 12 weeks prior to screening.
  6. Intramuscular, Intra-articular or IV within 4 weeks prior to screening.
  7. Receipt of live (attenuated) vaccine within the 4 weeks before Day 0.
  8. Treatment with hydroxychloroquine, cyclosporine A, azathioprine, cyclophosphamide, or mycophenolate mofetil (MMF) within 4 weeks of screening.
  9. Female subjects who are pregnant, intending to become pregnant, or are breastfeeding.
  10. Known history of allergy or reaction to any component of the mavrilimumab or placebo formulation or to any other biologic therapy or prednisone or any of its .
  11. Positive (or 2 indeterminate) QuantiFERON test results.
  12. active infection or infection requiring hospitalization or IV antibiotics within 12 weeks before screening or opportunistic infection within 6 months before screening.
  13. Chronic active infection.
  14. Subjects at a high risk of infection, a history of an infected joint prosthesis still in situ, leg ulcers, indwelling urinary catheter, or persistent or recurrent chest infections.
  15. History of cancer within the last 10 years, except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured.
  16. Evidence of clinically-uncontrolled respiratory disease.
  17. History of chronic respiratory tract infections.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    mavrilimumab

    Subjects randomized to mavrilimumab will receive 150 mg every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.

    Combination Product: mavrilimumab · Drug: prednisone

  • Placebo comparator
    placebo

    Subjects randomized to placebo will receive placebo every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.

    Combination Product: placebo · Drug: prednisone

Interventions

  • Combination productmavrilimumab

    1 mL of 150 mg in a pre-filled syringe

    Also known as: KPL-301

  • Combination productplacebo

    1 mL of placebo in a pre-filled syringe

  • Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)

06

What researchers measure

Primary outcomes

  1. Time to Flare by Week 26

    Time to flare by Week 26 was defined as time from randomization to the date of first flare occurring within the 26-week period, as assessed by independent adjudication. Kaplan-Meier method used to estimate the survival functions for each treatment arm. Flare/relapse was defined as a C-reactive protein (CRP) of 1 mg/dL or greater and/or erythrocyte sedimentation rate (ESR) of 30 mm/h or greater AND at least one of the following signs or symptoms attributed to GCA: Cranial symptoms (new-onset localized headache; scalp or temporal artery tenderness; ischemic-related vision loss; unexplained mouth or jaw pain upon mastication; transient ischemic attack or stroke related to GCA); Extracranial symptoms (claudication of the extremities; symptoms of polymyalgia rheumatica); New or worsening angiographic abnormalities detected via MRI, CT/CTA, or PET-CT of the aorta or other great vessels or via ultrasound of the temporal arteries.

    Time frame: Week 26

Secondary outcomes

  1. Sustained Remission Rate at Week 26

    The sustained remission rate at Week 26 is defined as the percentage of participants with sustained remission, as assessed by independent adjudication, at Week 26, derived from the time to flare curve. Kaplan-Meier Survival Estimates with standard error and 95% CI for each arm. Participants who completed the treatment period without a flare by Week 26 were considered to have sustained remission.

    Time frame: Week 26

  2. Time to Elevated Erythrocyte Sedimentation Rate (ESR) by Week 26

    Elevated ESR is defined as first occurrence of ESR value ≥ 30 mm/hr. Participants with elevated ESR within 3 days of first dose are excluded from the analysis. Kaplan-Meier method used to estimate the survival functions for each treatment arm.

    Time frame: Week 26

  3. Time to Elevated C-Reactive Protein (CRP) by Week 26

    Elevated CRP is defined as first occurrence of CRP value ≥ 1.0 mg/dL. Participants with elevated CRP within 3 days of first dose are excluded from the analysis. Kaplan-Meier method used to estimate the survival functions for each treatment arm.

    Time frame: Week 26

  4. Time to Signs/Symptoms of Giant Cell Arteritis (GCA) or New or Worsening Vasculitis on Imaging by Week 26

    Kaplan-Meier method used to estimate the survival functions for each treatment arm.

    Time frame: Week 26

  5. Cumulative Corticosteroid Dose at Week 26

    Time frame: Week 26

  6. Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal ESR

    Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.

    Time frame: Week 26

  7. Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal CRP Level

    Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.

    Time frame: Week 26

  8. Percentage of Participants Who Completed the 26-week Corticosteroid Taper and Who Had No Signs or Symptoms of GCA Nor New or Worsening Vasculitis by Imaging by Week 26

    Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.

    Time frame: Week 26

  9. Cumulative Corticosteroid Dose at the End of the Washout Safety Follow-up Period

    Time frame: Final Safety Follow-up visit (Week 38)

07

Results

Posted Oct 17, 2023

Participant flow

Participant flow — Overall Study
MilestoneMavrilimumabPlacebo
Started4228
Completed treatment3112
Completed3925
Not completed33
Withdrew: Adverse event10
Withdrew: Withdrawal by subject22
Withdrew: Lack of efficacy01

Outcome measures

PrimaryTime to Flare by Week 26

Time to flare by Week 26 was defined as time from randomization to the date of first flare occurring within the 26-week period, as assessed by independent adjudication. Kaplan-Meier method used to estimate the survival functions for each treatment arm. Flare/relapse was defined as a C-reactive protein (CRP) of 1 mg/dL or greater and/or erythrocyte sedimentation rate (ESR) of 30 mm/h or greater AND at least one of the following signs or symptoms attributed to GCA: Cranial symptoms (new-onset localized headache; scalp or temporal artery tenderness; ischemic-related vision loss; unexplained mouth or jaw pain upon mastication; transient ischemic attack or stroke related to GCA); Extracranial symptoms (claudication of the extremities; symptoms of polymyalgia rheumatica); New or worsening angiographic abnormalities detected via MRI, CT/CTA, or PET-CT of the aorta or other great vessels or via ultrasound of the temporal arteries.

Time frame:
Week 26
Reported as:
Median · weeks
Time to Flare by Week 26
weeksMavrilimumabPlacebo
Time to Flare by Week 26NA (NA to NA)25.1 (16.0 to NA)
Statistical analysis
  • Mavrilimumab vs Placebo · Log Rank · p = 0.0263 (Comparison of KPL-301 and placebo with respect to time to flare calculated by using a log-rank test stratified by randomization strata.) · Hazard ratio (hr): 0.38 · 95% CI 0.15 to 0.9295% confidence interval was calculated based on a Cox proportional-hazards model with treatment as covariate and stratified by randomization strata.
SecondarySustained Remission Rate at Week 26

The sustained remission rate at Week 26 is defined as the percentage of participants with sustained remission, as assessed by independent adjudication, at Week 26, derived from the time to flare curve. Kaplan-Meier Survival Estimates with standard error and 95% CI for each arm. Participants who completed the treatment period without a flare by Week 26 were considered to have sustained remission.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Sustained Remission Rate at Week 26
percentage of participantsMavrilimumabPlacebo
Sustained Remission Rate at Week 2683.2 (67.9 to 91.6)49.9 (29.6 to 67.3)
Statistical analysis
  • Mavrilimumab vs Placebo · normal approximation · p = 0.0038 (Two-sided p-value and 95% CI for the difference in sustained remission between two arms using normal approximation. Placebo arm is the reference.) · Difference in proportions: 33.3 · 95% CI 10.7 to 55.8
SecondaryTime to Elevated Erythrocyte Sedimentation Rate (ESR) by Week 26

Elevated ESR is defined as first occurrence of ESR value ≥ 30 mm/hr. Participants with elevated ESR within 3 days of first dose are excluded from the analysis. Kaplan-Meier method used to estimate the survival functions for each treatment arm.

Time frame:
Week 26
Reported as:
Median · weeks
Time to Elevated Erythrocyte Sedimentation Rate (ESR) by Week 26
weeksMavrilimumabPlacebo
Time to Elevated Erythrocyte Sedimentation Rate (ESR) by Week 2626.1 (16.1 to NA)12.1 (8.1 to 16.6)
Statistical analysis
  • Mavrilimumab vs Placebo · Log Rank · p = 0.0277 (Calculated by using a log-rank test stratified by randomization strata.) · Hazard ratio (hr): 0.51 · 95% CI 0.27 to 0.95Calculated based on a Cox proportional-hazards model with treatment as covariate, and stratified by randomization strata.
SecondaryTime to Elevated C-Reactive Protein (CRP) by Week 26

Elevated CRP is defined as first occurrence of CRP value ≥ 1.0 mg/dL. Participants with elevated CRP within 3 days of first dose are excluded from the analysis. Kaplan-Meier method used to estimate the survival functions for each treatment arm.

Time frame:
Week 26
Reported as:
Median · weeks
Time to Elevated C-Reactive Protein (CRP) by Week 26
weeksMavrilimumabPlacebo
Time to Elevated C-Reactive Protein (CRP) by Week 26NA (8.1 to NA)12.3 (3.3 to 24.1)
Statistical analysis
  • Mavrilimumab vs Placebo · Log Rank · p = 0.0378 (Calculated by using a log-rank test stratified by randomization strata.) · Hazard ratio (hr): 0.43 · 95% CI 0.19 to 0.98Calculated based on a Cox proportional-hazards model with treatment as covariate, and stratified by randomization strata.
SecondaryTime to Signs/Symptoms of Giant Cell Arteritis (GCA) or New or Worsening Vasculitis on Imaging by Week 26

Kaplan-Meier method used to estimate the survival functions for each treatment arm.

Time frame:
Week 26
Reported as:
Median · weeks
Time to Signs/Symptoms of Giant Cell Arteritis (GCA) or New or Worsening Vasculitis on Imaging by Week 26
weeksMavrilimumabPlacebo
Time to Signs/Symptoms of Giant Cell Arteritis (GCA) or New or Worsening Vasculitis on Imaging by Week 26NA (NA to NA)25.1 (15.1 to NA)
Statistical analysis
  • Mavrilimumab vs Placebo · Log Rank · p = 0.0651 (Calculated by using a log-rank test stratified by randomization strata.) · Hazard ratio (hr): 0.49 · 95% CI 0.22 to 1.06Calculated based on a Cox proportional-hazards model with treatment as covariate, and stratified by randomization strata.
SecondaryCumulative Corticosteroid Dose at Week 26
Time frame:
Week 26
Reported as:
Mean · mg
Cumulative Corticosteroid Dose at Week 26
mgMavrilimumabPlacebo
Cumulative Corticosteroid Dose at Week 262074.15 ± 708.4332402.98 ± 1014.446
Statistical analysis
  • Mavrilimumab vs Placebo · ANCOVA · p = 0.0667 (Calculated using ANCOVA with treatment arm and randomization strata as discrete variables, and corticosteroid starting dose as a continuous variable.) · Least squares (ls) means difference: -326.45 · 95% CI -675.99 to 23.09
SecondaryPercentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal ESR

Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal ESR
percentage of participantsMavrilimumabPlacebo
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal ESR45.2 (29.8 to 61.3)14.3 (4.0 to 32.7)
Statistical analysis
  • Mavrilimumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0201 (95% CI and p-value are analyzed using a Cochran-Mantel-Haenszel (CMH) test stratified by randomization strata) · Difference in percentages: 31.0 · 95% CI 11.1 to 50.8
SecondaryPercentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal CRP Level

Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal CRP Level
percentage of participantsMavrilimumabPlacebo
Percentage of Participants Who Completed the 26-Week Corticosteroid Taper and Who Had a Normal CRP Level23.8 (12.1 to 39.5)14.3 (4.0 to 32.7)
Statistical analysis
  • Mavrilimumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.5533 (95% CI and p-value are analyzed using a Cochran-Mantel-Haenszel (CMH) test stratified by randomization strata) · Difference in percentages: 9.5 · 95% CI -8.7 to 27.8
SecondaryPercentage of Participants Who Completed the 26-week Corticosteroid Taper and Who Had No Signs or Symptoms of GCA Nor New or Worsening Vasculitis by Imaging by Week 26

Participants were considered to have completed the corticosteroid taper if by week 26 receiving 1 mg/day for those who start with 60 mg/day, or 0 mg/day for those who start with doses \< 60 mg/day. 95% CI calculated using Clopper-Pearson confidence intervals.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Completed the 26-week Corticosteroid Taper and Who Had No Signs or Symptoms of GCA Nor New or Worsening Vasculitis by Imaging by Week 26
percentage of participantsMavrilimumabPlacebo
Percentage of Participants Who Completed the 26-week Corticosteroid Taper and Who Had No Signs or Symptoms of GCA Nor New or Worsening Vasculitis by Imaging by Week 2671.4 (55.4 to 84.3)32.1 (15.9 to 52.4)
Statistical analysis
  • Mavrilimumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0031 (95% CI and p-value are analyzed using a Cochran-Mantel-Haenszel (CMH) test stratified by randomization strata) · Difference in percentages: 39.3 · 95% CI 17.2 to 61.3
SecondaryCumulative Corticosteroid Dose at the End of the Washout Safety Follow-up Period
Time frame:
Final Safety Follow-up visit (Week 38)
Reported as:
Mean · mg
Cumulative Corticosteroid Dose at the End of the Washout Safety Follow-up Period
mgMavrilimumabPlacebo
Cumulative Corticosteroid Dose at the End of the Washout Safety Follow-up Period2464.93 ± 1106.6362845.45 ± 1320.115
Statistical analysis
  • Mavrilimumab vs Placebo · ANCOVA · p = 0.1629 (Calculated using ANCOVA with treatment arm and randomization strata as discrete variables, and corticosteroid starting dose as a continuous variable) · Least squares (ls) means difference: -380.82 · 95% CI -919.66 to 158.02

Adverse events

Collected over All-Cause Mortality: From signing of informed consent (up to 6 weeks prior to Baseline) through Final Safety Follow-up / Week 38 Adverse Events: from first dose of study drug through Final Safety Follow-up / Week 38. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mavrilimumab0/42 (0%)2/42 (4.8%)33/42 (78.6%)
Placebo0/28 (0%)3/28 (10.7%)25/28 (89.3%)
Most frequent serious events
Most frequent serious events
EventMavrilimumabPlacebo
Gastrointestinal haemorrhageGastrointestinal disorders0/421/28
Oedema peripheralGeneral disorders0/421/28
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders0/421/28
Hypertrophic cardiomyopathyCongenital, familial and genetic disorders1/420/28
DementiaNervous system disorders1/420/28
Most frequent other events
Showing 10 of 25
Most frequent other events
EventMavrilimumabPlacebo
HeadacheNervous system disorders6/427/28
FallInjury, poisoning and procedural complications2/425/28
ArthralgiaMusculoskeletal and connective tissue disorders2/424/28
HypertensionVascular disorders1/424/28
NasopharyngitisInfections and infestations5/423/28
DiarrheaGastrointestinal disorders0/423/28
Back painMusculoskeletal and connective tissue disorders3/423/28
Muscle spasmsMusculoskeletal and connective tissue disorders3/423/28
Carbon monoxide diffusing capacity decreasedInvestigations4/421/28
Neck painMusculoskeletal and connective tissue disorders4/422/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)MavrilimumabPlaceboTotal
Mean69.7 ± 6.9869.7 ± 8.3169.7 ± 7.48
Sex: Female, Male
Sex: Female, Male(Participants)MavrilimumabPlaceboTotal
Female321850
Male101020
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MavrilimumabPlaceboTotal
White402868
Other, Not Specified202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MavrilimumabPlaceboTotal
Hispanic or Latino123
Not Hispanic or Latino412667
08

Study locations

49 sites
  • Site 1703
    Sarasota, Florida 34239, United States
  • Site 1708
    Tampa, Florida 33612, United States
  • Site 1706
    Atlanta, Georgia 30342, United States
  • Site 1701
    Boston, Massachusetts 02114, United States
  • Site 1707
    Lansing, Michigan 48910, United States
  • Site 1704
    Saint Clair Shores, Michigan 48081, United States
  • Site 1702
    Rochester, Minnesota 55905-0001, United States
  • Site 1705
    New York, New York 10021, United States
  • Site 2102
    Kogarah, 2217, Australia
  • Site 2105
    Nedlands, 6009, Australia
  • Site 2106
    Parkville, 3050, Australia
  • Site 2101
    Victoria Park, 6100, Australia
  • Site 2104
    Woodville South, 5011, Australia
  • Site 2204
    Brussels, 1070, Belgium
  • Site 2202
    Leuven, 3000, Belgium
  • Site 2201
    Liège, 4000, Belgium
  • Site 2203
    Yvoir, 5530, Belgium
  • Site 2303
    Zagreb, 10 000, Croatia
  • Site 2401
    Tallinn, 11312, Estonia
  • Site 2402
    Tartu, 50708, Estonia
  • Site 2502
    Tuebingen, Baden-Württemberg 72076, Germany
  • Site 2504
    Erlangen, Bayern 91054, Germany
  • Site 2507
    Freiburg im Breisgau, 79106, Germany
  • Site 2506
    Hamburg, 22763, Germany
  • Site 2503
    Hannover, 30625, Germany
  • Site 2508
    Jena, 07747, Germany
  • Site 2501
    Kirchheim Unter Teck, 73230, Germany
  • Site 2601
    Dublin, D04 T6F4, Ireland
  • Site 2703
    Milano, 20132, Italy
  • Site 2701
    Pieve Emanuele, 20090, Italy
  • Site 2702
    Reggio Emilia, 42100, Italy
  • Site 2704
    Udine, 33100, Italy
  • Site 2802
    Groningen, 9713 GZ, Netherlands
  • Site 2801
    Rotterdam, 3015 GD, Netherlands
  • Site 2902
    Christchurch, 8083, New Zealand
  • Site 2901
    Wellington, 6021, New Zealand
  • Site 1002
    Kraków, 31-121, Poland
  • Site 1101
    Belgrade, 11000, Serbia
  • Site 1102
    Belgrade, 11000, Serbia
  • Site 1103
    Belgrade, 11000, Serbia
  • Site 1201
    Ljubljana, 1000, Slovenia
  • Site 1303
    A Coruña, 15006, Spain
  • Site 1301
    Barcelona, 08036, Spain
  • Site 1304
    Bilbao, 48013, Spain
  • Site 1302
    Santa Cruz De Tenerife, 38320, Spain
  • Site 1604
    Edinburgh, EH4 2XU, United Kingdom
  • Site 1603
    Essex, SS0 0RY, United Kingdom
  • Site 1602
    London, E11 1NR, United Kingdom
  • Site 1601
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Cid MC, Unizony SH, Blockmans D, Brouwer E, Dagna L, Dasgupta B, Hellmich B, Molloy E, Salvarani C, Trapnell BC, Warrington KJ, Wicks I, Samant M, Zhou T, Pupim L, Paolini JF; KPL-301-C001 Investigators. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022 May;81(5):653-661. doi: 10.1136/annrheumdis-2021-221865. Epub 2022 Mar 9. PubMed 35264321 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Aug 2020, 22 months.

Results were first posted in Oct 2023, 3 years 2 months after primary completion. A results delay was requested in Aug 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2019
First posted
Feb 1, 2019
StartActual
Sep 20, 2018
Primary completionActual
Aug 13, 2020
CompletionActual
Nov 25, 2020
Results delay requested
Aug 2, 2021
Results first posted
Oct 17, 2023
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03827018
Lead sponsor
Kiniksa Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Feb 1, 2019
Start date
Sep 20, 2018
Primary completion
Aug 13, 2020
Completion
Nov 25, 2020
Results posted
Oct 17, 2023
Last update
Oct 23, 2023

Study contacts

John Paolini, M.D.
study director · Kiniksa Pharmaceuticals, Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mavrilimumab

Start the discussion